[Alpha 1-protease inhibitor deficiency. Diagnosis, follow-up and therapy options]

T Köhnlein1, H Klein, T Welte

  • 1Klinik für Kardiologie, Angiologie und Pneumologie, Otto-von-Guericke-Universität Magdeburg. Thomas.Koehnlein@medizin.uni-magdeburg.de

Medizinische Klinik (Munich, Germany : 1983)
|August 7, 1999
PubMed

Insights

Alpha-1 antitrypsin deficiency, a common genetic disorder, significantly increases the risk of lung emphysema and liver disease in adults. Early diagnosis and treatment, including augmentation therapy, are crucial for managing this condition.

Area of Science:

  • Genetics and Medicine
  • Pulmonology
  • Hepatology

Context:

  • Alpha-1 antitrypsin (alpha-1) deficiency is a prevalent hereditary condition, particularly in Caucasians.
  • It is a significant underlying cause of chronic obstructive pulmonary disease (COPD) and lung emphysema.
  • Affects approximately 2% of COPD and emphysema patients.

Purpose:

  • To highlight the clinical significance of alpha-1 antitrypsin deficiency.
  • To emphasize the importance of early diagnosis and intervention.
  • To outline current diagnostic and therapeutic strategies.

Summary:

  • Characterized by reduced levels of alpha-1 antitrypsin, the body's primary antiprotease.
  • Presents a high risk for lung emphysema in young adults (30-45 years), with symptoms including cough, sputum, and respiratory insufficiency.
  • A moderate risk of liver disease is also associated with this deficiency.

Impact:

  • Early detection through serum level measurement is vital for preventing pulmonary function decline.
  • Management includes physiotherapy, medications, and antibiotics.
  • Intravenous augmentation therapy with purified alpha-1 antitrypsin offers a direct treatment approach.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...